Neural Analytics aims robotic transcranial doppler at COVID-19 patients
Doctors are reporting a proliferation of dangerous blood clots in the lungs and other major organs of COVID-19 patients, raising the risk of stroke and other life-threatening complications. While anticoagulant medications can reduce that risk, patients need careful monitoring to ensure their blood is neither too thick nor too thin. To that end, Los Angeles-based startup Neural Analytics Inc. is deploying its robotically assisted transcranial doppler (TCD) system for real-time identification of blood clots and disruptions in blood flow to the brain.
Read More →
FDA greenlights ICU AI for predicting fatal COVID-19 complications
The company’s CLEWICU artificial intelligence software ingests a large range of patient data by linking to electronic medical records, connected medical devices and vital sign monitors, with no need for additional data entry by ICU staff. The FDA also said the standalone CLEWICU software, based within the hospital or in the cloud, could help reduce contact between healthcare workers and COVID-19 patients through remote monitoring.
Read More →
Bardy Diagnostics® Announces CE Mark Certification for 14-Day Carnation® Ambulatory Monitor (CAM®) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis
"CE marking of the 14-Day CAM patch is a significant corporate milestone and a testament to the quality of the CAM patch and BardyDx's compliance with all applicable European health, safety, performance and environmental requirements," said Ed Vertatschitsch, Chief Operating Officer.
Read More →
Alleviant Medical completes $6.5m offering
Congestive heart failure treatment developer Alleviant Medical filed an SEC Form D to confirm the sale of $6.5 million in an equity offering. The Austin, Texas-based company reached its total offering amount of $6.5 million after making the first sale in the new notice on May 1. It had no intention of letting the offering last longer than one year and did not make it in connection with a business transaction.
Read More →
PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology
PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.
Read More →
PyrAmes Is Granted Breakthrough Device Designation for Boppli, a Continuous, Non-Invasive Blood Pressure Monitoring System
Breakthrough Device Designation has the potential to accelerate our plans to bring Boppli to market to improve medical care for babies in need of better blood pressure monitoring.
Read More →
Houston’s Allotrope Medical wins 2020 Texas A&M New Ventures Competition
Dr. Albert Huang’s company Allotrope Medical took home the top $50,000 prize for the StimSite technology, which is a smooth muscle stimulation technology that allows surgeons to rapidly and safely identify critical tissue structures, like the ureter, during surgery.
Read More →
Day Zero Diagnostics wins $6.2m from accelerator
Boston-based Day Zero said in a news release that its system helps offer the most effective antibiotic treatment on the first day that patients are admitted to the hospital, rather than having them undergo multiple days of toxic broad-spectrum antibiotics to prevent septic shock.
Read More →
Genetesis lands strategic investment to close $9.2M Series B
Genetesis Inc, a medical technology company that has developed non-invasive, biomagnetic CardioFluxTM imaging, today announced several important updates. The company has closed significant strategic investments from TDK Ventures and an undisclosed Fortune 500 global, healthcare company, completing a $9.2M Series B financing. The round included participation by return investors CincyTech, Ohio Innovation Fund and Mark Cuban.
Read More →
Antibody testing for COVID-19 prepares for its closeup in bid to ease pandemic restrictions
San Diego-based Abreos Biosciences Inc. is looking to create a multiplex test that goes beyond the simple yes/no COVID-19 antibody results and measures the “specific flavors” of antibodies to provide a more complete picture of the antibodies in a person’s blood.
Read More →